Karniol I G, Portela W
Braz J Med Biol Res. 1982 Dec;15(6):389-94.
Tardive dyskinesia is a syndrome of involuntary movements that develops during or following long-term neuroleptic treatment. Current treatment of tardive dyskinesia is unsatisfactory. Neuroleptics can reduce the syndrome, but the underlying pathogenetic process is probably aggravated during treatment. The use of these drugs is necessary, however, when the patient simultaneously exhibits intense psychotic and dyskinetic symptoms. In this controlled study, 8 patients were treated with a beta-blocker drug, oxprenolol, as a slow-release preparation that was administered in increasing doses up to 640 mg per day for one month. We conclude that this drug can ameliorate both the psychotic features of schizophrenics and their tardive dyskinetic movements without producing significant side-effects.
迟发性运动障碍是一种在长期使用抗精神病药物治疗期间或之后出现的不自主运动综合征。目前对迟发性运动障碍的治疗并不令人满意。抗精神病药物可以减轻该综合征，但在治疗过程中潜在的致病过程可能会加重。然而，当患者同时出现强烈的精神病性症状和运动障碍症状时，使用这些药物是必要的。在这项对照研究中，8名患者接受了β受体阻滞剂氧烯洛尔治疗，采用缓释制剂，剂量逐渐增加至每日640毫克，持续一个月。我们得出结论，这种药物可以改善精神分裂症患者的精神病性症状及其迟发性运动障碍，且不会产生明显的副作用。
